Sequence information
Variant position: 1651 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1863 The length of the canonical sequence.
Location on the sequence:
SVSREKPELTASTERVNKRM
S MVVSGLTPEEFMLVYKFARK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SVSREKPELTASTERVNKRMS MVVSGLTPEEFMLVYKFARK
Gorilla SVSREKPELTASTERVNKRMS MVVSGLTPEEFMLVYKFARK
SVGIEKPEVISSTRGVNKRIS MVASGLTPKEFMLVHKFARK
Rhesus macaque SVSRENPKLTASTERVNKRMS LVVSGLTPEEFMLVYKFARR
Chimpanzee SVSREKPELTASTERVNKRMS MVVSGLTPEEFMLVYKFARK
Mouse IVSKIKPELTSSEERADRDIS MVVSGLTPKEVMTVQKFAEK
Rat IVSKIKPEVTSPKERAERDIS MVVSGLTPKEVMIVQKFAEK
Bovine SMSKEKPEVISSTERSKKRLS MVASGLTPKELMLVQKFARK
Caenorhabditis elegans --------------------- ---------------RFAED
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1863
Breast cancer type 1 susceptibility protein
Domain
1642 – 1736
BRCT 1
Alternative sequence
64 – 1863
Missing. In isoform 2.
Mutagenesis
1655 – 1655
S -> A. Abolishes interaction with BRIP1.
Mutagenesis
1656 – 1656
G -> D. No effect on affinity for a BRIP1 phosphopeptide.
Mutagenesis
1662 – 1662
F -> S. Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
Mutagenesis
1663 – 1663
M -> K. Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
Mutagenesis
1666 – 1666
Y -> A. Does not abolish ABRAXAS1 binding, but impairs formation of a heterotetramer with ABRAXAS1.
Mutagenesis
1670 – 1670
R -> E. Impairs formation of a heterotetramer with ABRAXAS1.
Mutagenesis
1671 – 1671
K -> E. Impairs formation of a heterotetramer with ABRAXAS1.
Beta strand
1651 – 1656
Literature citations
A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P.; van der Gulden H.; van der Heijden I.; Drost R.; Klijn C.N.; Prasetyanti P.; Pieterse M.; Wientjens E.; Seibler J.; Hogervorst F.B.; Jonkers J.;
Cancer Discov. 3:1142-1155(2013)
Cited for: CHARACTERIZATION OF VARIANTS BC PHE-4; THR-18; GLN-45; GLY-61; GLY-64; TYR-67; LYS-132; HIS-142; PHE-147; PRO-165; TRP-170; TYR-186; ILE-191; MET-231; VAL-245; VAL-246; LEU-271; PHE-668; ASN-695; LEU-798; TYR-810; LYS-826; GLN-841; HIS-856; ASN-1101; ASN-1140; GLY-1140; LYS-1214; LYS-1236; SER-1267; VAL-1282; SER-1297 DEL; ARG-1301; LYS-1346; ILE-1378; VAL-1400; PRO-1407; THR-1411; GLY-1443; GLY-1448; CYS-1486; MET-1534; PRO-1589; THR-1628; PRO-1651; PHE-1651; PHE-1655; ARG-1686; GLN-1686; VAL-1688 DEL; ILE-1691; TRP-1699; GLN-1699; GLU-1706; ALA-1706; GLU-1708; CYS-1718; ALA-1720; LYS-1735; ALA-1736; GLY-1739; VAL-1739; GLN-1746; THR-1753; PRO-1764; SER-1767; VAL-1770; CYS-1782; THR-1789; ASP-1794; ASP-1804; ARG-1812; ARG-1837 AND LEU-1862; VARIANTS CYS-105; CYS-866; ALA-1060; LYS-1250 AND ILE-1652;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.